[Latin Name] Vaccinium myrtillus l.

[Plant Source] Wild bilberry fruit cultivated from Sweden & Finland

[Specifications]

1) Anthocyanidins 25% UV (Glycosyl removed)

2) Anthocyanins 25% HPLC

3) Anthocyanins 36% HPLC

[Particle size] 80 Mesh

[Loss on drying] ≤5.0%

[Heavy Metal] ≤10PPM

[Pesticide residue] EC396-2005, USP 34, EP 8.0, FDA

[Storage] Store in cool & dry area, keep away from the direct light and heat.

[Package] Packed in paper-drums and two plastic-bags inside.

[General feature]

1. 100% extracted from European bilberry fruit, approved ID test from ChromaDex andAlkemist Lab;

2.Without any adultery of other relative species of Berries,such as Blueberry,  Mulberry,Cranberry,etc;

3. Pesticide residue: EC396-2005, USP 34, EP 8.0, FDA

4. Directly import the frozen fruit from North Europe;

5. Perfect water solubility,water insolubles<1.0%
6. Chromatographic fingerprint match EP6 requirement

[What is bilberry fruit]

Bilberry (Vaccinium Myrtillus L.) is a kind of perennial deciduous or evergreen fruit shrubs, mainly found in subarctic regions of the world as in Sweden, Finland and Ukraine, etc. Bilberries contain dense levels of anthocyanin pigments, which was said popularly to have been used by World War II RAF pilots to sharpen night vision. In fork medicine, Europeans have been taking bilberry for a hundred years. Bilberry extracts entered the healthcare market as a kind of dietary supplement for effects on vision enhancement and visual fatigue relief.

[Function]

Protect and regenerate rhodopsin and cure the eye diseases;

Prevent the cardiovascular diseases

Antioxidant and anti-aging

Softening blood capillary, enhancing the heart function and resisting cancer

Flaxseeds have the highest amount of lignans – up to 800 times any other plant – which are cancer fighting compounds. Flaxseed helps fight constipation, inflammation, and contains high levels of omega 3 fatty acids, which are good for healthy hearts.

For details, please visit https://foodandremedy.com/recipes/powders/flaxseed-chutney-powder/

Jose S. Pulido, M.D., Professor of Opthalmology & Molecular Medicine, Mayo Clinic College of Medicine and Alan D. Marmorstein, Ph.D., Professor of Ophthalmology, Mayo Clinic College of Medicine discuss the importance of genetic testing in diagnosing macular degeneration. Three cases are outlined that have been referred to as Adult Onset Foveomacular Dystrophy, Macular Degeneration, and Best Disease. Genetic testing can be used to make these diagnoses and researchers are at the threshold of new and exciting treatments. Over the past few years Dr. Marmorstein’s laboratory has been involved in a study of stem cell models of Best Disease and other retinal degenerative diseases. Details can be found on the NIH web site. DNA is being collected along with skin fibroblasts from patients with Best Disease Adult Vitelliform Dystrophy Autosomal Recessive Bestrophinopathy, autosomal dominant vitreoretinal choroidopathy, and retinitis pigmentosa due to mutations in BEST1. The skin fibroblasts are being reprogrammed into induced pluripotent stem cells which can be differentiated into retinal pigment epithelial cells. This is the cell where Bestrophin, the product of the BEST1 gene is expressed and that’s where the pathogenic problem that results in these diseases occurs. Clinical trials are already underway using iPS cell derived retinal pigment epithelial cells for the treatment of age-related Macular Degeneration. It also allows the consideration of the same process to therapeutically treat Best Disease and Adult Vitelliform Macular Dystrophy, Autosomal Recessive Bestrophinopathy and models of the diseases can be generated of the diseases in the laboratory. This can help with the understanding of the processes that cause the disease and allow for the testing of potential therapeutic compounds to determine if they have an effect on these specific patients.

For more information, visit: https://www.mayoclinic.org/departments-centers/ophthalmology?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=video&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504